Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD

Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β2-adrenoceptor agonists Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 Inhibitors: A Potential Treatment for Asthma Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a β2 adrenoceptor agonist Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogs Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma